|
Boston Millennia Partners Press Releases 2009
Boston, MA - November 4, 2009
Portfolio Company Athenix Sold for $400 Million to Bayer, a 10X return to BMP
Boston Millennia Partners pleased to announce that its portfolio company, Athenix Corporation, has been acquired by Bayer CropScience for $400 million. This is the second BMP II portfolio company sold for a 10X return.
VC Experts.com Staff - October 7, 2009
The VC Expert's Buzz Interview with Dana Callow,
In depth interview discussing the state of the VC industry, exciting investment sectors, status of the IPO market, current lending environment, advice to entrepreneurs, and investing in healthcare/life sciences industry.
Lugano, Switzerland - January 28, 2009
HELSINN ANNOUNCES THE ACQUISITION OF SAPPHIRE THERAPEUTICS INC., USA TO ESTABLISH HELSINN THERAPEUTICS (US) INC.
Today the Swiss pharmaceutical group Helsinn announced the acquisition, of the US biopharmaceutical company, Sapphire Therapeutics Inc. with headquarters in Bridgewater, New Jersey, for an undisclosed amount.
Portfolio Company Press Releases 2009
Monheim, Germany - November 2, 2009
Bayer CropScience Completes $400 Million Acquisition of Biotech Company Athenix Corp.
Bayer CropScience announced the completion of its purchase of Athenix Corp. which significantly boosts Bayer CropScience´s ability to make available to growers worldwide novel technology and complete agricultural solutions.
American Way - September 1, 2009
Cultivating Second Chances
Have an achy knee? Maybe you need to grow some new cartilage for it. Article From American Way Magazine regarding BMP's portfolio company Histogenics.
Boston, MA - June 1, 2009
PAREXEL Named as One of the Top 10 Publicly Traded Companies Based in Massachusetts
The Boston Globe, the premier daily newspaper in the Boston area where PAREXEL’s headquarters office is located, recently ranked PAREXEL # 10 in its list of the region’s top 100 businesses.
Cambridge, MA - May 27, 2009
CombinatoRx Reports Positive Phase 2 Trial Results for CRx-401
CombinatoRx reported positive results for its Phase 2 clinical study of CRx-401 as an add-on to metformin therapy in Type 2 diabetes which demonstrated that CRx-401 performed statistically significantly better than bezafibrate on the primary efficacy endpoint.
Boston, MA - May 19, 2009
Dartmouth-Hitchcock Medical Center Selects MedAptus for Charge Capture Deployment
Dartmouth-Hitchcock Clinic will be broadening its deployment of the MedAptus Professional offering, Practice Plus Edition.
Boston, MA - May 13, 2009
University of Minnesota Physicians Chooses MedAptus Following Comprehensive Vendor Review
MedAptus today announced that University of Minnesota Physicians (UMP), a premier multi-specialty physician organization, has selected MedAptus’ Practice Plus Edition for charge capture automation.
Boston, MA - May 7, 2009
MedAptus’ Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice
MedAptus announced that the distinguished Lenox Hill Interventional Cardiac & Vascular Services, PC (LHICVS) is the latest cardiology group to implement Professional Intelligent Charge Capture.
Cambridge, MA - May, 6, 2009
CombinatoRx Announces Oncology Collaboration with Novartis
CombinatoRx announced a strategic alliance with Novartis focused on the discovery of novel anti-cancer combinations.
Boston, MA - April 16, 2009
MedAptus Expands Board of Directors
MedAptus announced the addition of two new, independent directors, Linda Beneze and Laurence J. Hagerty, to its Board of Directors.
Lexington, MA - April 7, 2009
EPIX Pharmaceuticals Commences Exchange Offer for $100 Million Convertible Notes
EPIX announced that it has commenced an exchange offer for all of its $100 million aggregate principal amount of 3.00% Convertible Senior Notes due 2024 (the "Exchange Offer").
Boston, MA - April 6, 2009
PHT Corporation Names Finance Industry Senior Executive John J. Arcari as CFO
PHT Corporation announced that John J. Arcari, CPA, MBA, joined the company as Chief Financial Officer, reporting directly to PHT President and CEO Phil Lee.
Boston, MA - March 19, 2009
MedAptus Secures $6 Million Investment
MedAptus announced that it has secured $6 million in capital in a financing led by existing investor, Boston Millennia Partners. This investment will enable MedAptus to further support the growth of its Intelligent Charge Capture suite of products.
Lexington, MA - March 17, 2009
EPIX Pharmaceuticals Issued Composition of Matter Patent on Novel 5-HT4 Receptor Agonists
EPIX announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,488,736 entitled “Thienopyridinone Compounds and Methods of Treatment” to EPIX.
The American Medical Group Associations (AMGA) Group Practice Journal - March 15, 2009
MedAptus solution at Lahey Clinic is cover story in the March 2009 edition
Article highlights the deployment methodology and savings realized with MedAptus' Facility Charge Capture solution at the Lahey Clinic Medical Center. Indicates that initial feedback from the clinical staff regarding usage was of the tool was not just positive, it was euphoric.
Boston, MA - March 10, 2009
PHT Corporation Total Bookings Increase by 68% in 4th Fiscal Quarter as Overall eClinical Industry Adoption Accelerates
PHT Corporation is celebrating its most successful fourth fiscal quarter and year since the company’s founding in 1994.
Lexington, MA - March 5, 2009
EPIX Pharmaceuticals Appoints Elkan Gamzu, Ph.D., as Permanent CEO
EPIX Pharmaceuticals announced that its Board of Directors has appointed Elkan Gamzu, Ph.D., as president and chief executive officer and as a member of the Board, effective immediately. Dr. Gamzu had served in the role of interim chief executive officer of EPIX since July 2008.
Chicago, IL - February 27, 2009
Novalar™ Announces the Launch of OraVerse™ the First Dental Anesthesia Reversal Agent
Novalar announced the launch of OraVerse, the company’s dental pharmaceutical product. OraVerse is the first local anesthesia reversal agent that accelerates the return to normal sensation and function for patients who want to avoid the unwanted and unnecessary lingering soft tissue anesthesia.
Cambridge, MA - January 28, 2009
CombinatoRx Publishes Data on Selective Amplification of Synergistic Combination Drug Candidate
CombinatoRx publishes new in vivo research in Arthritis Research and Therapy on a systems biology based strategy that selectively amplifies the anti-inflammatory activity of very low dose glucocorticoids in immune cells without modulation of pathways associated with glucocorticoid toxicity.
Danbury, CT - January 26, 2009
Odyssey Logistics & Technology Corporation Announces Strong Double Digit Revenue Growth for 2008
In a state-of-the-business communication, Robert Shellman, chief executive officer of Odyssey Logistics & Technology Corporation, announced that the company experienced revenue growth in excess of 60% in its Managed Logistics Services sector for the full year 2008.
Des Moines, IA - January 15, 2009
DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans
DuPont and Athenix today announced they have entered into a research collaboration to improve insect control in corn and soybeans.
Atlanta, GA - January 12, 2009
GaBio Names Grace Powers, Emerging Leader of the Year
Grace Powers, a Regulatory Affairs Specialist at CardioMEMS, Inc. was named the 2009 Emerging Leader of the Year by Georgia Bio (GaBio).
Cumberland, RI - January 8, 2009
Collegium Pharmaceutical Announces FDA Approval of AllerNaze™, a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis
Collegium announced that the FDA has approved AllerNaze™ Nasal Spray, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children 12 years and older.
Boston, MA - January 7, 2009
Kentucky Medical Services Foundation Completes Successful Charge Capture Technology Conversion
MedAptus announced that Kentucky Medical Services Foundation, Inc. (KMSF) has successfully implemented Professional Intelligent Charge Capture for more than 250 physician-users.
Boston, MA - January 6, 2009
PHT Corporation Achieves ISO 9001:2000 Recertification from TUV Rheinland
PHT Corporation announced TUV Rheinland of North America has recertified PHT as compliant with the ISO 9001:2000 standard.
All Other Nexidia Press Releases
Click Here for all Nexidia Press Releases
|
